0
Skip to Content
BLOODPAC
BLOODPAC
About
Our Story
Our Team
Our Community
Annual Reports & Financials
Contact Us
Approach
How We Work
Reimbursement & Policy
Public Comments
Collaborative Studies
Data
BLOODPAC Portal
BLOODPAC Data Commons
Impact
BLOODPAC Publications
Data Elements
Frameworks & Standards
Member Publications
BLOODPAC Events
Resources
BLOODPAC Governance
Insights
Videos
MEMBER LOGIN
BLOODPAC
BLOODPAC
About
Our Story
Our Team
Our Community
Annual Reports & Financials
Contact Us
Approach
How We Work
Reimbursement & Policy
Public Comments
Collaborative Studies
Data
BLOODPAC Portal
BLOODPAC Data Commons
Impact
BLOODPAC Publications
Data Elements
Frameworks & Standards
Member Publications
BLOODPAC Events
Resources
BLOODPAC Governance
Insights
Videos
MEMBER LOGIN
Folder: About
Back
Our Story
Our Team
Our Community
Annual Reports & Financials
Contact Us
Folder: Approach
Back
How We Work
Reimbursement & Policy
Public Comments
Collaborative Studies
Folder: Data
Back
BLOODPAC Portal
BLOODPAC Data Commons
Folder: Impact
Back
BLOODPAC Publications
Data Elements
Frameworks & Standards
Member Publications
BLOODPAC Events
Folder: Resources
Back
BLOODPAC Governance
Insights
Videos
MEMBER LOGIN
BLOODPAC and JCO Precision Oncology Conversations
News Dorys Lopez 5/28/24 News Dorys Lopez 5/28/24

BLOODPAC and JCO Precision Oncology Conversations

Lauren Leiman, Executive Director at BLOODPAC and Dr. Emma Alme, Public Policy Director at Guardant Health sat down with JCO Podcast host, Dr. Rafeh Naqash to discuss accessibility to liquid biopsy for cancer, potential barriers and proposed solutions.

Read More
BLOODPAC and Epic Sciences: Building Collaboration
News Laura Tramontozzi 6/4/20 News Laura Tramontozzi 6/4/20

BLOODPAC and Epic Sciences: Building Collaboration

Read More

ABOUT

BLOODPAC is a consortium managed by the Center for Computational Science Research, Inc. (CCSR), which is an Illinois based 501 (c)(3) not-for-profit corporation. Our mission is to accelerate the development, validation, and accessibility of liquid biopsy assays to improve outcomes for patients with cancer. To do so, we lead a pre-competitive collaborative infrastructure that enables the sharing of information and building of consensus among stakeholders in industry, academia, regulatory bodies, payers, and government agencies.